NO321775B1 - Fremgangsmate for a hemme endotelcelleproliferasjon in vitro, farmasoytisk blanding som omfatter en endotelcelleproliferasjons-inhibitor, samt anvendelse. - Google Patents

Fremgangsmate for a hemme endotelcelleproliferasjon in vitro, farmasoytisk blanding som omfatter en endotelcelleproliferasjons-inhibitor, samt anvendelse. Download PDF

Info

Publication number: NO321775B1
Authority: NO; Norway
Prior art keywords: inhibitor; protein; amino acid; acid sequence; endothelial cell
Prior art date: 1995-12-13

Application number

NO19982715A

Other languages

English (en)

Norwegian (no)

Other versions

NO982715L (no

NO982715D0 (no

Inventor

Michael S O'reilly

Yihai Cao

Moses Folkman

Original Assignee

Children S Medical Ct Corp The

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-12-13

Filing date

1998-06-12

Publication date

2006-07-03

1996-12-12 Priority claimed from US08/763,528 external-priority patent/US5854221A/en

1998-06-12 Application filed by Children S Medical Ct Corp The filed Critical Children S Medical Ct Corp The

1998-06-12 Publication of NO982715D0 publication Critical patent/NO982715D0/no

1998-08-12 Publication of NO982715L publication Critical patent/NO982715L/no

2006-07-03 Publication of NO321775B1 publication Critical patent/NO321775B1/no

Links

238000000034 method Methods 0.000 title claims description 42
210000002889 endothelial cell Anatomy 0.000 title claims description 36
230000004663 cell proliferation Effects 0.000 title claims description 29
230000002401 inhibitory effect Effects 0.000 title claims description 20
238000000338 in vitro Methods 0.000 title claims description 15
239000003112 inhibitor Substances 0.000 title description 156
230000008569 process Effects 0.000 title description 8
239000008194 pharmaceutical composition Substances 0.000 title description 2
206010028980 Neoplasm Diseases 0.000 claims description 69
108090000765 processed proteins & peptides Proteins 0.000 claims description 55
108090000623 proteins and genes Proteins 0.000 claims description 53
239000000203 mixture Substances 0.000 claims description 52
102000004169 proteins and genes Human genes 0.000 claims description 46
230000033115 angiogenesis Effects 0.000 claims description 36
150000001413 amino acids Chemical class 0.000 claims description 29
201000010099 disease Diseases 0.000 claims description 28
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
101000605403 Homo sapiens Plasminogen Proteins 0.000 claims description 18
201000011510 cancer Diseases 0.000 claims description 15
102000013566 Plasminogen Human genes 0.000 claims description 10
108010051456 Plasminogen Proteins 0.000 claims description 10
230000001404 mediated effect Effects 0.000 claims description 10
230000002491 angiogenic effect Effects 0.000 claims description 8
238000011282 treatment Methods 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 2
125000003275 alpha amino acid group Chemical group 0.000 claims 12
239000003814 drug Substances 0.000 claims 2
229940079593 drug Drugs 0.000 claims 2
210000001519 tissue Anatomy 0.000 description 23
239000003153 chemical reaction reagent Substances 0.000 description 20
108010033276 Peptide Fragments Proteins 0.000 description 18
102000007079 Peptide Fragments Human genes 0.000 description 18
210000004027 cell Anatomy 0.000 description 18
102000004196 processed proteins & peptides Human genes 0.000 description 18
238000009472 formulation Methods 0.000 description 16
230000012010 growth Effects 0.000 description 15
102000005962 receptors Human genes 0.000 description 14
108020003175 receptors Proteins 0.000 description 14
229940024606 amino acid Drugs 0.000 description 13
230000027455 binding Effects 0.000 description 13
230000004614 tumor growth Effects 0.000 description 13
206010027476 Metastases Diseases 0.000 description 12
230000000694 effects Effects 0.000 description 12
206010029113 Neovascularisation Diseases 0.000 description 11
238000004458 analytical method Methods 0.000 description 11
239000012634 fragment Substances 0.000 description 11
241001465754 Metazoa Species 0.000 description 10
210000004204 blood vessel Anatomy 0.000 description 10
210000004881 tumor cell Anatomy 0.000 description 10
239000000284 extract Substances 0.000 description 9
238000001727 in vivo Methods 0.000 description 9
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 8
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
230000009401 metastasis Effects 0.000 description 8
150000007523 nucleic acids Chemical group 0.000 description 8
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 7
108091028043 Nucleic acid sequence Proteins 0.000 description 7
239000005557 antagonist Substances 0.000 description 7
210000004369 blood Anatomy 0.000 description 7
239000008280 blood Substances 0.000 description 7
210000001124 body fluid Anatomy 0.000 description 7
239000010839 body fluid Substances 0.000 description 7
150000001875 compounds Chemical class 0.000 description 7
239000002254 cytotoxic agent Substances 0.000 description 7
229940127089 cytotoxic agent Drugs 0.000 description 7
231100000599 cytotoxic agent Toxicity 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
239000013598 vector Substances 0.000 description 7
241000283973 Oryctolagus cuniculus Species 0.000 description 6
239000000556 agonist Substances 0.000 description 6
238000003556 assay Methods 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
239000011159 matrix material Substances 0.000 description 6
238000000746 purification Methods 0.000 description 6
238000003127 radioimmunoassay Methods 0.000 description 6
238000012360 testing method Methods 0.000 description 6
230000002792 vascular Effects 0.000 description 6
108020004414 DNA Proteins 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 5
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
230000001419 dependent effect Effects 0.000 description 5
229940088598 enzyme Drugs 0.000 description 5
230000014509 gene expression Effects 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
108091006086 inhibitor proteins Proteins 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
238000010647 peptide synthesis reaction Methods 0.000 description 5
239000012071 phase Substances 0.000 description 5
229920000747 poly(lactic acid) Polymers 0.000 description 5
238000000163 radioactive labelling Methods 0.000 description 5
210000002700 urine Anatomy 0.000 description 5
102000008076 Angiogenic Proteins Human genes 0.000 description 4
108010074415 Angiogenic Proteins Proteins 0.000 description 4
241000283690 Bos taurus Species 0.000 description 4
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
239000000427 antigen Substances 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
210000002469 basement membrane Anatomy 0.000 description 4
229920002988 biodegradable polymer Polymers 0.000 description 4
239000004621 biodegradable polymer Substances 0.000 description 4
239000000872 buffer Substances 0.000 description 4
210000001043 capillary endothelial cell Anatomy 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
239000007788 liquid Substances 0.000 description 4
230000004807 localization Effects 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
-1 polyvinylpropylene Polymers 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
230000005747 tumor angiogenesis Effects 0.000 description 4
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 3
208000003788 Neoplasm Micrometastasis Diseases 0.000 description 3
206010003246 arthritis Diseases 0.000 description 3
239000013060 biological fluid Substances 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
230000008859 change Effects 0.000 description 3
210000004087 cornea Anatomy 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
238000001514 detection method Methods 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
230000006870 function Effects 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
238000003364 immunohistochemistry Methods 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
230000009871 nonspecific binding Effects 0.000 description 3
230000001575 pathological effect Effects 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
210000002381 plasma Anatomy 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
238000003752 polymerase chain reaction Methods 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
238000011160 research Methods 0.000 description 3
239000007787 solid Substances 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
230000029663 wound healing Effects 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
206010005003 Bladder cancer Diseases 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
244000003240 Caesalpinia gilliesii Species 0.000 description 2
235000014161 Caesalpinia gilliesii Nutrition 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
230000004544 DNA amplification Effects 0.000 description 2
206010012689 Diabetic retinopathy Diseases 0.000 description 2
108050009340 Endothelin Proteins 0.000 description 2
102000002045 Endothelin Human genes 0.000 description 2
208000010412 Glaucoma Diseases 0.000 description 2
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
208000002260 Keloid Diseases 0.000 description 2
208000006552 Lewis Lung Carcinoma Diseases 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
241000699660 Mus musculus Species 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
229920000954 Polyglycolide Polymers 0.000 description 2
206010060862 Prostate cancer Diseases 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
208000017442 Retinal disease Diseases 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
206010043189 Telangiectasia Diseases 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
206010052428 Wound Diseases 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
239000004037 angiogenesis inhibitor Substances 0.000 description 2
229940121369 angiogenesis inhibitor Drugs 0.000 description 2
230000002482 anti-endothelial effect Effects 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
239000000969 carrier Substances 0.000 description 2
235000011472 cat’s claw Nutrition 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
239000006143 cell culture medium Substances 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
239000006071 cream Substances 0.000 description 2
210000004748 cultured cell Anatomy 0.000 description 2
230000006378 damage Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
238000002405 diagnostic procedure Methods 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
230000003511 endothelial effect Effects 0.000 description 2
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 2
210000003038 endothelium Anatomy 0.000 description 2
210000003989 endothelium vascular Anatomy 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
239000000499 gel Substances 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
201000011066 hemangioma Diseases 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
206010020718 hyperplasia Diseases 0.000 description 2
239000007943 implant Substances 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
238000007917 intracranial administration Methods 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
210000001117 keloid Anatomy 0.000 description 2
239000004310 lactic acid Substances 0.000 description 2
235000014655 lactic acid Nutrition 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
239000002502 liposome Substances 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
208000002780 macular degeneration Diseases 0.000 description 2
239000000463 material Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
244000005700 microbiome Species 0.000 description 2
238000000386 microscopy Methods 0.000 description 2
210000004088 microvessel Anatomy 0.000 description 2
230000002107 myocardial effect Effects 0.000 description 2
230000010046 negative regulation of endothelial cell proliferation Effects 0.000 description 2
230000017066 negative regulation of growth Effects 0.000 description 2
201000003142 neovascular glaucoma Diseases 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
239000006187 pill Substances 0.000 description 2
210000002826 placenta Anatomy 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
238000002600 positron emission tomography Methods 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
239000000523 sample Substances 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000002798 spectrophotometry method Methods 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
208000009056 telangiectasis Diseases 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
201000005112 urinary bladder cancer Diseases 0.000 description 2
210000004291 uterus Anatomy 0.000 description 2
238000012800 visualization Methods 0.000 description 2
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 1
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
208000003120 Angiofibroma Diseases 0.000 description 1
208000022211 Arteriovenous Malformations Diseases 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
241000282465 Canis Species 0.000 description 1
241001631457 Cannula Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
229920001287 Chondroitin sulfate Polymers 0.000 description 1
208000032544 Cicatrix Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
206010011017 Corneal graft rejection Diseases 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
241000589989 Helicobacter Species 0.000 description 1
101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
102000004890 Interleukin-8 Human genes 0.000 description 1
208000012659 Joint disease Diseases 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
102100038609 Lactoperoxidase Human genes 0.000 description 1
108010023244 Lactoperoxidase Proteins 0.000 description 1
206010027457 Metastases to liver Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
201000004404 Neurofibroma Diseases 0.000 description 1
MSHZHSPISPJWHW-PVDLLORBSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)NC(=O)CCl)C[C@@]21CO2 MSHZHSPISPJWHW-PVDLLORBSA-N 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
206010037649 Pyogenic granuloma Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
201000000582 Retinoblastoma Diseases 0.000 description 1
206010038933 Retinopathy of prematurity Diseases 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
241000473945 Theria <moth genus> Species 0.000 description 1
241000390203 Trachoma Species 0.000 description 1
GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 1
241000700605 Viruses Species 0.000 description 1
239000002253 acid Substances 0.000 description 1
208000004064 acoustic neuroma Diseases 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
230000003321 amplification Effects 0.000 description 1
210000002159 anterior chamber Anatomy 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
210000001742 aqueous humor Anatomy 0.000 description 1
230000005744 arteriovenous malformation Effects 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
230000006399 behavior Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
239000000560 biocompatible material Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
238000010170 biological method Methods 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
238000005415 bioluminescence Methods 0.000 description 1
230000029918 bioluminescence Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
201000008275 breast carcinoma Diseases 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
230000032823 cell division Effects 0.000 description 1
210000001627 cerebral artery Anatomy 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
210000003837 chick embryo Anatomy 0.000 description 1
VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
229940059329 chondroitin sulfate Drugs 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
229960005188 collagen Drugs 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
230000002254 contraceptive effect Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
210000004246 corpus luteum Anatomy 0.000 description 1
230000008878 coupling Effects 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
208000030381 cutaneous melanoma Diseases 0.000 description 1
230000002380 cytological effect Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
230000005059 dormancy Effects 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
210000004696 endometrium Anatomy 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
230000008556 epithelial cell proliferation Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
208000030533 eye disease Diseases 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000008175 fetal development Effects 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
229940126864 fibroblast growth factor Drugs 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
NGGMYCMLYOUNGM-CSDLUJIJSA-N fumagillin Chemical class C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O)C[C@@]21CO2 NGGMYCMLYOUNGM-CSDLUJIJSA-N 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000011132 hemopoiesis Effects 0.000 description 1
230000001744 histochemical effect Effects 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000002390 hyperplastic effect Effects 0.000 description 1
230000001969 hypertrophic effect Effects 0.000 description 1
238000003365 immunocytochemistry Methods 0.000 description 1
230000002055 immunohistochemical effect Effects 0.000 description 1
238000012309 immunohistochemistry technique Methods 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000016507 interphase Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000000185 intracerebroventricular administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
230000009545 invasion Effects 0.000 description 1
208000030776 invasive breast carcinoma Diseases 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
210000004153 islets of langerhan Anatomy 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
229940057428 lactoperoxidase Drugs 0.000 description 1
230000003902 lesion Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
210000001365 lymphatic vessel Anatomy 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
230000005906 menstruation Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
208000037819 metastatic cancer Diseases 0.000 description 1
230000006510 metastatic growth Effects 0.000 description 1
208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
230000036963 noncompetitive effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
238000011580 nude mouse model Methods 0.000 description 1
230000016087 ovulation Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
210000003668 pericyte Anatomy 0.000 description 1
210000004303 peritoneum Anatomy 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000003169 placental effect Effects 0.000 description 1
229920001308 poly(aminoacid) Polymers 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
230000002028 premature Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
201000001514 prostate carcinoma Diseases 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
230000037387 scars Effects 0.000 description 1
208000011581 secondary neoplasm Diseases 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
201000003708 skin melanoma Diseases 0.000 description 1
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
239000004296 sodium metabisulphite Substances 0.000 description 1
235000010262 sodium metabisulphite Nutrition 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
241000894007 species Species 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000011285 therapeutic regimen Methods 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
206010044325 trachoma Diseases 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
230000007704 transition Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000032258 transport Effects 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
210000003556 vascular endothelial cell Anatomy 0.000 description 1
230000004862 vasculogenesis Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000008215 water for injection Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)
Toxicology (AREA)
Oncology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Farming Of Fish And Shellfish (AREA)
Medicines Containing Plant Substances (AREA)

NO19982715A 1995-12-13 1998-06-12 Fremgangsmate for a hemme endotelcelleproliferasjon in vitro, farmasoytisk blanding som omfatter en endotelcelleproliferasjons-inhibitor, samt anvendelse. NO321775B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US851995P	1995-12-13	1995-12-13
US08/763,528 US5854221A (en)	1996-12-12	1996-12-12	Endothelial cell proliferation inhibitor and method of use
PCT/US1996/020447 WO1997023500A1 (en)	1995-12-13	1996-12-13	Endothelial cell proliferation inhibitor and method of use

Publications (3)

Publication Number	Publication Date
NO982715D0 NO982715D0 (no)	1998-06-12
NO982715L NO982715L (no)	1998-08-12
NO321775B1 true NO321775B1 (no)	2006-07-03

Family

ID=26678280

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19982715A NO321775B1 (no)	1995-12-13	1998-06-12	Fremgangsmate for a hemme endotelcelleproliferasjon in vitro, farmasoytisk blanding som omfatter en endotelcelleproliferasjons-inhibitor, samt anvendelse.

Country Status (19)

Country	Link
US (1)	US20010016644A1 (da)
EP (1)	EP0869970B1 (da)
JP (1)	JP3684371B2 (da)
KR (1)	KR100477280B1 (da)
CN (1)	CN1554444A (da)
AT (1)	ATE262537T1 (da)
AU (1)	AU710612B2 (da)
BR (1)	BR9612115A (da)
CA (1)	CA2240296C (da)
CZ (1)	CZ298612B6 (da)
DE (1)	DE69631972T2 (da)
DK (1)	DK0869970T3 (da)
ES (1)	ES2217340T3 (da)
HU (1)	HUP9900979A3 (da)
NO (1)	NO321775B1 (da)
NZ (1)	NZ330537A (da)
PL (1)	PL188719B1 (da)
PT (1)	PT869970E (da)
WO (1)	WO1997023500A1 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ298612B6 (cs) *	1995-12-13	2007-11-21	The Children's Medical Center Corporation	Inhibitor proliferace endothelových bunek a jeho použití
US6057122A (en)	1996-05-03	2000-05-02	Abbott Laboratories	Antiangiogenic peptides polynucleotides encoding same and methods for inhibiting angiogenesis
US5801146A (en) *	1996-05-03	1998-09-01	Abbott Laboratories	Compound and method for inhibiting angiogenesis
US6699838B1 (en)	1996-05-03	2004-03-02	Abbott Laboratories	Antiangiogenic peptides
US5801012A (en)	1996-09-17	1998-09-01	Northwestern University	Methods and compositions for generating angiostatin
JP2002510209A (ja) *	1997-06-26	2002-04-02	カロリンスカイノベイションズアクチボラゲット	インビボで血管形成を調節することができるプラスミノーゲンのクリングルドメイン１−５
WO1999026480A1 (en) *	1997-11-20	1999-06-03	Genetix Pharmaceuticals, Inc.	Anti-angiogenic gene therapy vectors and their use in treating angiogenesis-related diseases
US6632961B1 (en)	1998-05-22	2003-10-14	Abbott Laboratories	Antiangiogenic drug to treat cancer, arthritis and retinopathy
JP4209086B2 (ja) *	1999-05-17	2009-01-14	コンジュケムバイオテクノロジーズインコーポレイテッド	長期持続性抗新脈管形成ペプチド
US7144854B1 (en)	1999-09-10	2006-12-05	Conjuchem, Inc.	Long lasting anti-angiogenic peptides
BR0010750A (pt)	1999-05-17	2002-02-26	Conjuchem Inc	Peptìdeos insulinotrópicos de longa duração
AU784359B2 (en) *	1999-12-15	2006-03-16	Entremed, Inc	Compositions and methods for inhibiting endothelial cell proliferation
AU8591901A (en)	2000-09-05	2002-03-22	Karolinska Innovations Ab	Materials and methods relating to endothelial cell growth inhibitors
AU2002239414A1 (en) *	2000-11-02	2002-05-27	Bristol-Myers Squibb Company	Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors
EP2444805A3 (en) *	2004-01-21	2012-06-20	Fujirebio America, Inc.	Detection of mesothelin-/megakaryocyte potentiating factor-related peptides in peritoneal fluid for assessment of the peritoneum and the peritoneal cavity
CN100355458C (zh) *	2005-03-16	2007-12-19	北京大学	人增殖抑制基因－腺病毒表达载体的应用
EP2435562A1 (en)	2009-05-26	2012-04-04	Biolex Therapeutics, Inc.	Compositions and methods for production of aglycosylated plasminogen
CN103060265B (zh) *	2013-01-23	2014-12-03	山东大学	老年大鼠脑血管内皮细胞原代培养方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4929444A (en) *	1985-05-28	1990-05-29	Burroughs Wellcome Co.	Low pH pharmaceutical formulation containing t-PA
US5149533A (en) *	1987-06-04	1992-09-22	Zymogenetics, Inc.	Modified t-PA with kringle-/replaced by another kringle
US5302390A (en) *	1987-07-01	1994-04-12	Beecham Group Plc	Hybrid proteins of human plasminogen and human t-PA, pharmaceutical compositions and methods of treatment
US5491129A (en) *	1992-07-30	1996-02-13	Yeda Research And Development Co. Ltd.	Synthetic peptides derived from vitronectin and pharmaceutical compositions comprising them
EP0758393A1 (en) *	1994-04-26	1997-02-19	PHARMACIA & UPJOHN COMPANY	Mac-1 i-domain protein useful in blocking adhesion and migration of neutrophils
ATE355379T1 (de) *	1994-04-26	2006-03-15	Childrens Medical Center	Angiostatin und verfahren zu seiner nutzung zur vermeidung der angiogenese
NZ307044A (en) *	1995-04-26	2002-03-01	Childrens Medical Center	Angiostatin fragments with antiangiogenic activity
CZ298612B6 (cs) *	1995-12-13	2007-11-21	The Children's Medical Center Corporation	Inhibitor proliferace endothelových bunek a jeho použití

1996
- 1996-12-13 CZ CZ0182898A patent/CZ298612B6/cs not_active IP Right Cessation
- 1996-12-13 KR KR10-1998-0704447A patent/KR100477280B1/ko not_active Expired - Fee Related
- 1996-12-13 AT AT96945635T patent/ATE262537T1/de active
- 1996-12-13 CA CA002240296A patent/CA2240296C/en not_active Expired - Fee Related
- 1996-12-13 NZ NZ330537A patent/NZ330537A/en not_active IP Right Cessation
- 1996-12-13 CN CNA2004100432779A patent/CN1554444A/zh active Pending
- 1996-12-13 AU AU16870/97A patent/AU710612B2/en not_active Ceased
- 1996-12-13 PL PL96327200A patent/PL188719B1/pl unknown
- 1996-12-13 DE DE69631972T patent/DE69631972T2/de not_active Expired - Lifetime
- 1996-12-13 DK DK96945635T patent/DK0869970T3/da active
- 1996-12-13 JP JP52383197A patent/JP3684371B2/ja not_active Expired - Fee Related
- 1996-12-13 ES ES96945635T patent/ES2217340T3/es not_active Expired - Lifetime
- 1996-12-13 WO PCT/US1996/020447 patent/WO1997023500A1/en not_active Ceased
- 1996-12-13 BR BR9612115A patent/BR9612115A/pt not_active Application Discontinuation
- 1996-12-13 PT PT96945635T patent/PT869970E/pt unknown
- 1996-12-13 EP EP96945635A patent/EP0869970B1/en not_active Expired - Lifetime
- 1996-12-13 HU HU9900979A patent/HUP9900979A3/hu unknown
1998
- 1998-06-12 NO NO19982715A patent/NO321775B1/no not_active IP Right Cessation
2000
- 2000-12-29 US US09/753,064 patent/US20010016644A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NO982715L (no)	1998-08-12
AU1687097A (en)	1997-07-17
BR9612115A (pt)	1999-02-17
CA2240296A1 (en)	1997-07-03
CZ182898A3 (cs)	1998-10-14
WO1997023500A1 (en)	1997-07-03
AU710612B2 (en)	1999-09-23
NZ330537A (en)	2001-06-29
JP3684371B2 (ja)	2005-08-17
EP0869970A4 (en)	2002-01-30
PL188719B1 (pl)	2005-04-29
PL327200A1 (en)	1998-11-23
EP0869970A1 (en)	1998-10-14
DK0869970T3 (da)	2004-07-05
KR19990072126A (ko)	1999-09-27
ES2217340T3 (es)	2004-11-01
CA2240296C (en)	2004-05-04
DE69631972T2 (de)	2005-01-05
KR100477280B1 (ko)	2005-07-18
ATE262537T1 (de)	2004-04-15
HK1017692A1 (zh)	1999-11-26
EP0869970B1 (en)	2004-03-24
PT869970E (pt)	2004-08-31
HUP9900979A2 (hu)	1999-07-28
CN1554444A (zh)	2004-12-15
HUP9900979A3 (en)	2001-10-29
CZ298612B6 (cs)	2007-11-21
DE69631972D1 (de)	2004-04-29
US20010016644A1 (en)	2001-08-23
NO982715D0 (no)	1998-06-12
JP2002502359A (ja)	2002-01-22

Legal Events

Date	Code	Title	Description
2015-07-27	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
US5792845A (en)	1998-08-11	Nucleotides encoding angiostatin protein and method of use
US5854221A (en)	1998-12-29	Endothelial cell proliferation inhibitor and method of use
IL113509A (en)	2005-12-18	Angiostatin protein compositions and methods of use
JP3840262B2 (ja)	2006-11-01	治療用の抗血管新生組成物および方法
NO321775B1 (no)	2006-07-03	Fremgangsmate for a hemme endotelcelleproliferasjon in vitro, farmasoytisk blanding som omfatter en endotelcelleproliferasjons-inhibitor, samt anvendelse.
US20030114370A1 (en)	2003-06-19	Nucleic acid molecules encoding endostatin protein and peptide fragments thereof
CN101307106B (zh)	2013-06-12	内皮细胞增殖抑制剂及其应用方法
AU2008201326B2 (en)	2010-01-21	Therapeutic antiangiogenic endostatin compositions
HK1017692B (en)	2009-04-17	Endothelial cell proliferation inhibitor and method of use
HK1104576A (en)	2008-01-18	Angiostatin and method of use for inhibition of angiogenesis
HK1070279A (en)	2005-06-17	Endothelial cell proliferation inhibitor and method of use
MXPA99011041A (en)	2001-05-17	Angiostatin fragments and method of use